Aditxt subsidiary Pearsanta has acquired patents associated with adductomics-based DNA damage detection, to make significant advancements in cancer diagnostics.
Valued at nearly $1m, the acquisition involved the issuance of Pearsanta’s convertible preferred stock.
Go deeper with GlobalData
This move aligns with the company’s mission to progress accessible early cancer identification and prevention worldwide.
The patents cover proprietary progressions in DNA adduct detection and analysis, which can evaluate genomic instability that occurred due to environmental toxins and metabolic byproducts.
DNA adducts are chemical modifications to DNA nucleotides that occur due to carcinogens and are among the earliest indicators of cancer risk.
Pearsanta’s Mitomic Technology platform leverages biomarkers of mitochondrial DNA for “non-invasive” detection of cancer.
The company’s acquisition enables it to expand its capabilities in assessing carcinogen exposure and genomic instability before the occurrence of permanent mutations.
Over the next two to three years, Pearsanta will focus on clinical validation, regulatory submissions along with commercialisation activities for integrating the technology into its diagnostic portfolio.
By using urine, blood, or solid tissue samples, the company plans to “develop” its platform as a comprehensive assessment tool for DNA adducts, offering actionable insights into the damage of DNA.
The company is progressing with a strategic development plan to introduce adductomics-based diagnostics to the market.
This includes the focus on clinical validation for confirming the “effectiveness” of the technology, regulatory submissions for supporting integration into laboratory-developed tests (LDTs), and scalability within labs certified by Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP).
By identifying DNA damage prior to disease progression, the adductomics technology claims to “reduce” the overall economic load of cancer.
Pearsanta president Chris Mitton said: “We believe that Pearsanta is uniquely positioned to shift cancer care from reactive treatment to proactive prevention.
“In underserved regions, where access to oncology treatments remains limited, we believe that adductomics-based screening could provide a cost-effective tool for early cancer risk assessment, empowering preventive measures when they are most effective.”
